Hantz Financial Services Inc. Boosts Stake in Illumina, Inc. $ILMN

Hantz Financial Services Inc. raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 100.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,087 shares of the life sciences company’s stock after buying an additional 3,554 shares during the period. Hantz Financial Services Inc.’s holdings in Illumina were worth $930,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in shares of Illumina by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after purchasing an additional 124,246 shares in the last quarter. Elo Mutual Pension Insurance Co acquired a new stake in Illumina during the 3rd quarter worth $2,319,000. Caprock Group LLC purchased a new position in Illumina during the 3rd quarter worth $1,479,000. Nordea Investment Management AB grew its position in Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after purchasing an additional 911,843 shares during the last quarter. Finally, Capital World Investors grew its position in Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 3.4%

ILMN opened at $150.17 on Thursday. The stock has a market capitalization of $22.72 billion, a PE ratio of 27.30, a P/E/G ratio of 2.40 and a beta of 1.42. Illumina, Inc. has a 12-month low of $78.79 and a 12-month high of $155.53. The firm’s fifty day moving average price is $132.17 and its 200 day moving average price is $131.55. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the company earned $0.97 earnings per share. The firm’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts expect that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Citigroup boosted their price objective on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research report on Thursday, May 14th. Finally, Canaccord Genuity Group dropped their price target on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research report on Friday, May 1st. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $137.75.

Insider Activity

In other news, Director Keith A. Meister sold 225,067 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the completion of the transaction, the director owned 3,604,441 shares in the company, valued at approximately $524,626,387.55. This trade represents a 5.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the transaction, the senior vice president owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 330,160 shares of company stock worth $48,028,308. 2.90% of the stock is owned by corporate insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.